Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TriLipix Approval Strengthens Abbott’s Cholesterol Franchise

Executive Summary

FDA approval of Abbott's next-generation fenofibrate TriLipix (fenofibric acid) reinforces the drug maker's position in the lucrative but maturing cholesterol market
Advertisement

Related Content

Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD
AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix
Solvay Analyzing “Various Options” For Its Pharma Unit
TriLipix Exceeding Abbott’s Expectations Shortly After Launch, Execs Say
TriLipix Exceeding Abbott’s Expectations Shortly After Launch, Execs Say
Abbott, AstraZeneca Riding Crestor Wave With Expanded Partnership
Abbott, AstraZeneca Riding Crestor Wave With Expanded Partnership
Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo
Abbott’s Phase III Fenofibrate Works With Statins
Advertisement
UsernamePublicRestriction

Register

PS050487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel